Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard ...

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, to step down as company seeks a turnaround. Company found success with Wegovy and Ozempic, but share price has fallen by half in past year.

Novo Nordisk (NVO) is in focus on Friday after its long-time chief executive Lars Fruergaard Jørgensen announced his resignation following a mutual agreement with the board. Fruergaard will ...

Lars Fruergaard Jorgensen had led Denmark’s Novo since 2017. Ritzau Scanpix/AFP via Getty Images. He told Reuters that discussions to replace Jorgensen had taken place over the past few weeks.

Lars Fruergaard Jorgensen’s departure comes a week after the company downgraded its sales and profits forecast and follows a more than 50% decline in the company’s shares since mid-2024.

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.

LONDON — Lars Fruergaard Jørgensen, who led Novo Nordisk as it rode the boom of its obesity and diabetes medications to become one of the biggest players in pharma, only to see that success ...

It’s the end of an era at Novo as longtime CEO Lars Fruergaard Jørgensen—who shepherded the company through its GLP-1 growth boom—heads for the exit.

Lars Fruergaard Jørgensen joined Novo Nordisk in 1991 and was appointed chief executive officer in January 2017. During his time at the helm, the company has grown tremendously, fortified its ...